anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The British Association of Oral and Maxillofacial Surgeons (BAOMS) Quality and Outcomes in Oral and Maxillofacial Surgery (QOMS) reconstructive audit aims to provide surgical teams with risk adjusted comparative performance data. The goal is to enable surgeons to optimise surgical pathways. Risk adjustment requires that data on appropriate predictive variables are collected. This study looked at variables predicting major complications and flap failure in a single institution with the aim of determining whether the QOMS dataset adequately captures the appropriate data points. A prospective database of head and neck flap procedures and associated postoperative complications has been maintained in the maxillofacial surgery department since August 2009 up to August 2022 (n=1327). A total of 25 putative risk variables were extracted from the health records for each patient. The outcomes of interest were total flap failure and major complications. Independent predictors of flap failure were recipient site (sinonasal/anterior skull base), previous major surgery, previous major surgery and radiotherapy, and flap selection. For major complications ACE-27 comorbidity score, flap type, use of tracheostomy, elevated preoperative plasma C-reactive protein (CRP) and flap selection were independently predictive. Apart from preoperative activated innate immunity all relevant risk stratification variables identified in this study form part of the QOMS dataset. QOMS is therefore likely to adequately risk stratify patients based upon currently collected variables.
Patients enrolled in the SI screw removal treatment group will undergo the surgery 5-9 months after the initial SI screw stabilization surgery. The surgeon will remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
Primary renal hypouricemia (RHUC) is a rare autosomal recessive disorder with a mean duration of end-stage acute kidney injury (EIAKI) of 14 days. The pathogenesis of EIAKI in patients with RHUC remains unclear. Several hypotheses have been proposed, including those related to the renal vasoconvulsive effect and the elevating effect of xanthine oxidase (XO). The effect of xanthine oxidase (XO) is most often observed following strenuous anaerobic exercise, which is frequently accompanied by low back pain, nausea, and acute kidney injury (AKI). Consequently, we postulate that EIAKI could be prevented by avoiding strenuous exercise, thus preventing the onset and recurrence of EIAKI. In this paper, we present a case of recurrent EIAKI in a patient with RHUC and a mutation in the SLC2A9 gene.
Codeine: Codeine may increase serum amylase levels.

Acetaminophen: Acetaminophen may produce false positive test results for urinary 5‑hydroxyindoleacetic acid. 

### 5.21 FD&C Yellow No. 5 (Tartrazine) 

This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject, combined with rituximab 1g(D1, D31 respectively, intravenous infusion). Add 1 g rituximab at 6 months.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to industrial poultry breeding. Method includes processing of surface of objects for zootechnical control of incubator, incubated eggs with water solution of preparation based on quaternary ammonium compound. As water solution based on quaternary ammonium compound used is 0.05-0.2% water solution of composition from trimethyloctadecyl ammonium bromide - 40%, trimethyloctadecyl ammonium iodide - 40% and trimethyloctadecyl ammonium acetate - 20%. Said solution is used to process objects for zootechnical control of incubator and incubated eggs 2-4 hours before putting eggs for incubation. ^ EFFECT: method makes it possible to increase breeding of young poultry and increase its preservation. ^ 1 tbl, 1 ex
PROBLEM TO BE SOLVED: To obtain a skin cosmetic which has excellent anti-inflammatory effect and an excellent beautifully whitening effect, has high stability and skin safety, and can express an excellent use touch by adding a specific dihydroxyphenyl compound as an active ingredient. SOLUTION: This skin cosmetic contains a dihydroxyphenyl compound of formula I and/or a dihydroxyphenyl compound of formula II as active ingredients. The compound of formula I is easily obtained, for example, by cleaving the methyl ether group of zingherone contained in ginger with boron tribromide and hydroiodic acid. The compound of formula II can also be obtained by reducing the zingherone with sodium borohydride in the same manner as above. The compounds are preferably added in an amount of 0.01-5.0 wt.% based on the total amount of the skin cosmetic. Thereby, the excellent skin cosmetic which can express an inhibitory effect on the inflammation and melanization of skin due to ultraviolet light, and the quick hypochromic effect on melanized skin and has high skin safety, and the like, is provided.
PURPOSE:To obtain the title compsn. which can remove metal ions adsorbed to hair, by mixing a particular monosalt of a collagen peptide acylated with a higher fatty acid with an anionic surfactant. CONSTITUTION:5-95wt.% monosalt (A) of a collagen peptide a cylated with a higher fatty acid contg. at least 50wt.% of a component of formula I [wherein R is a 9-19C straight-chain or branched alkyl or alkenyl; X and Y are various amino acids exclusive of glutamic acid or aspartic acid contained in a collagen peptide; m and n are each 0 or greater with the proviso that 1<=m+n<=9; p is up to 5 with the proviso that 2<=(m+n+1)Xp<=10; M is an alkali metal or an onium of ammonia, an org. amine, a basic amino acid or a polyethyleneimine; Glu is glutamic acid; and Asp is aspartic acid, with the proviso that Glu or Asp is necessarily contained as a constitutive amino acid] is mixed with up to 1/3 by wt. of the wt. of component (A) and up to 1/5 by wt. of the wt. of component (A) in terms of ash content as sulfate salt, of an anionic surfactant (B) [e.g., an alkylbenzenesulfonate salt of formula II (wherein R1 is a 10-18C alkyl; and M is an alkali metal or an onium of ammonia etc.)], optionally together with a hydrolyzed protein, a phosphate deriv., etc. (C).
<P>PROBLEM TO BE SOLVED: To achieve the cloning of DNA synthesis-inhibiting factors with functional assays.  <P>SOLUTION: An expression vector cDNA library derived from senescent cells has been used to isolate cDNA clones that encode DNA synthesis-inhibiting factors. Such inhibiting factors play a role in cellular senescence and aging and tumor formation. The present invention relates to the molecules, the inhibiting factors, antagonists, antisense nucleic acids against such the molecules and derivatives. The present invention relates to the diagnostic, therapeutic and in vitro uses of such the all medicinal ingredients.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
PURPOSE: To provide a composition effective for bone strengthening of an osteoporosis patient of mainly aged people or a school child in a growth period. CONSTITUTION: This composition having bone strengthening action contains a basic protein fraction derived from milk and calcium derived from milk. This composition may be ingested in a shape of an oral administrating formulation or foods and drinks. Preferably, at least 50mg/100g of a basic protein fraction derived from milk and at least 250mg/100g of calcium derived from milk are contained in the case of foods, and at least 77mg/100g and 380mg/100g are contained respectively in the case of drinks. Absorbability of calcium is significantly increased with the composition having bone strengthening action and the bone strengthening action is reinforced. In the case of foods and drinks, the composition may be ingested in usual eating habit and effective for bone strengthening of an osteoporosis patient or a school child in a growing period.
Since the first description of Nelson syndrome 60 years ago, the way to consider corticotroph pituitary neuroendocrine tumors (PitNETs) after bilateral adrenalectomy has evolved. Today, it is globally acknowledged that only a subset of corticotroph PitNETs is aggressive.After adrenalectomy, corticotroph tumor progression (CTP) occurs in about 30 to 40% of patients during a median follow-up of 10 years. When CTP occurs, various CTP speeds (CTPS) can be observed. Using simple metrics in patients with CTP, CTPS was reported to vary from a few millimeters to up to 40 mm per year. Rapid CTPS/ Nelson's syndrome was associated with more severe Cushing's disease, higher adrenocorticotropic hormone (ACTH) in the year following adrenalectomy, and higher Ki67 on pituitary pathology. Complications such as apoplexy, cavernous syndrome, and visual defects were associated with higher CTPS. During follow-up, early morning ACTH, absolute variations properly reflected CTPS. Finally, CTPS was not higher after than before adrenalectomy, suggesting that cortisol deprivation after adrenalectomy does not impact CTPS in a majority of patients.Taken together, rapid CTPS/ Nelson's syndrome probably reflects the intrinsic aggressiveness of some corticotroph PitNETs. The precise molecular mechanisms related to corticotroph PitNET aggressiveness remain to be deciphered. Regular MRIs combined with intermediate morning ACTH measurements probably provide a reliable way to detect early and manage fast-growing tumors and, therefore, limit the complications.
AZD4547 will be given orally twice daily until disease progression. Patients will also receive MEDI 4736 (durvalumab) by IV infusion once every 4 weeks.
To provide systems and medical formulations suitable for delivering therapeutic powders to a target site.SOLUTION: A system comprises a delivery device, a first powder formed from particles of a first material, and a second powder formed from particles of a second material, where the second material is different than the first material. At least some of the particles of the first and second powders are bound together to form bonded particles. The bonded particles are simultaneously delivered to the target site by the delivery device. The first powder comprises a mucoadhesive agent, and the second powder comprises a hemostatic agent. The difference between the density of the particles of the first powder and the density of the particles of the second powder is at least two times. The mucoadhesive agent comprises carbomer, and the hemostatic agent comprises bentonite or plant-based polysaccharides.SELECTED DRAWING: Figure 1A
Inflammation through activation of caspase-1, seems to play a role in pulmonary hypertension induced by alveolar hypoxia. Whether alveolar hypoxia induces caspase-1-mediated inflammation and influx of leukocytes in other organs than the lungs, is not known. Our aim was to explore sites of caspase-1-related inflammation in alveolar hypoxia. Wild type (WT) mice were exposed to environmental hypoxia or room-air, and organs were analyzed. Right heart catheterization was performed after 14 days of alveolar hypoxia in WT mice and mice transplanted with WT or caspase-1-/- bone marrow. Hypoxia induced leukocyte accumulation and increased caspase-1 protein in the lungs, not in other organs. WT mice transplanted with WT or caspase-1-/- bone marrow showed no difference in pulmonary leukocyte accumulation or development of pulmonary hypertension after alveolar hypoxia. Caspase-1 and IL-18 were detected in bronchial epithelium in WT mice, and hypoxia induced IL-18 secretion from bronchial epithelial cells. IL-18 stimulation generated IL-6 mRNA in monocytes. Phosphorylated STAT3 was increased in hypoxic lungs, not in other organs. Alveolar hypoxia induces caspase-1 activation and leukocyte accumulation specific to the lungs, not in other organs. Caspase-1 activation and IL-18 secretion from bronchial epithelial cells might initiate hypoxia-induced inflammation, leading to pulmonary hypertension.
Background: Complex decongestive therapy (CDT) is being used in breast cancer-related lymphedema (BCRL). The degree of initial edema and bioimpedance analysis (BIA) are known to be related with the therapeutic effect of CDT. D-dimer can indirectly reflect lymphangiogenesis because IL-6 regulates D-dimer and vascular endothelial growth factor, which is the most important lymphangiogenic factor. We assessed whether D-dimer could be used for the prediction of therapeutic effect of CDT, as well as BIA and initial edema. Methods: The participants were patients who took inpatient treatment for BCRL from July 2016 to May 2020. Percent excess volume (PEV) was calculated by dividing the difference in volume of both arms by the edema arm, and the difference in PEV before and after 2 weeks of CDT was defined as the CDT effect. BIA and D-dimer tests were performed before treatment. Results: The single frequency bioimpedance analysis (SFBIA) ratio and D-dimer showed significant correlations with β coefficients of 0.581 and 0.402 (p < 0.01), respectively, and the explanatory power of these models was confirmed to be 0.704.The areas under the curve of initial PEV, SFBIA ratio, D-dimer for determining the CDT effect were identified as 0.849, 0.795, and 0.725, respectively. Conclusions: Initial PEV, SFBIA ratio, and blood D-dimer levels could be used as predictors for CDT treatment effect. Their usefulness order was in the order of initial PEV, SFBIA ratio, and D-dimer. These factors could be used as predictors to establish therapeutic plan in patients with mild lymphedema.
WARNINGS  
Respiratory Depression – Pediatrics  
Promethazine hydrochloride injection should not be used in pediatric patients less than 2 years of age because of the potential for fatal respiratory depression. Postmarketing cases of respiratory depression, including fatalities, have been reported with use of promethazine in pediatric patients less than 2 years of age. Caution should be exercised when administering promethazine hydrochloride injection to pediatric patients 2 years of age and older (see WARNINGS - Respiratory Depression). 

Severe Tissue Injury, Including Gangrene   
Promethazine hydrochloride injection can cause severe chemical irritation and damage to tissues regardless of the route of administration. Irritation and damage can result from perivascular extravasation, unintentional intra-arterial injection, and intraneuronal or perineuronal infiltration. Adverse reactions include burning, pain, thrombophlebitis, tissue necrosis, and gangrene. In some cases, surgical intervention, including fasciotomy, skin graft, and/or amputation have been required (see WARNINGS - Severe Tissue Injury, Including Gangrene). 

Due to the risks of intravenous injection, the preferred route of administration of promethazine hydrochloride injection is deep intramuscular injection. Subcutaneous injection is contraindicated. See DOSAGE AND ADMINISTRATION for important notes on administration.
Psilocybin with facilitated counseling: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
PROBLEM TO BE SOLVED: To provide a constipation-improving composition enabling a comfortable defecation without accompanying a violent diarrhea. SOLUTION: This constipation-improving composition contains pantothenic acid and/or its alkali salt, Bacillus bifidus, edible fibers, and preferably further an ingredient having a laxative action as active ingredients. The edible fibers stabilizes the pantothenic acid and its calcium salt. Pantetheine, pantethine, and coenzyme A biologically synthesized from the pantothenic acid and its calcium salt carry out an action for stimulating the movements of intestinal tracts, and proliferate the Bacillus bifidus. Thereby, the composition can reasonably improve constipation, and enables a comfortable defecation without accompanying a violent diarrhea. The ingredient having a laxative action promotes a mild defecation and can regulate the functions of bowels for a long period.
This study aims to explore the impacts of ApoB-100/SORT1-mediated immune microenvironment during acute spinal cord injury (SCI), and to investigate the potential mechanism. CB57BL/6 mice underwent moderate thoracic contusion injury to establish the SCI animal model, and received ApoB-100 lentivirus injection to interfere ApoB-100 level. Functional recovery was assessed using the Basso, Beattie, and Bresnahan (BBB) score and footprint analysis. Transmission electron microscopy was applied to observe the ultrastructure of the injured spinal cord tissue. Hematoxylin-eosin (HE) staining and Perls staining were conducted to assess histological changes and iron deposition. Biochemical factor and cytokines were detected using their commercial kits. M1/M2 macrophage markers were detected by immunofluorescence assay in vivo and by flow cytometry in vitro. HT22 neurons were simulated by lipopolysaccharide (LPS), followed by incubation with polarized macrophage medium to simulate the immune microenvironment of injured spinal cord in vitro. The local immune microenvironment is changed in SCI mice, accompanied with the occurrence of oxidative stress and the elevation of both M1 and M2 macrophages. Knockdown of ApoB-100 ameliorates oxidative stress and lipid disorder, and inhibits inflammation and ferroptosis in SCI mice. Importantly, knockdown of ApoB-100 can partly restrict M1 macrophages but does not change M2 macrophage proportion in SCI mice. Further, M1 macrophages are observed to attenuate the inflammatory response, oxidative stress, and ferroptosis levels of LPS-induced HT22 cells, which is further strengthened by SORT1 knockdown. Blockage of ApoB-100/SORT1-mediated immune microenvironment plays a protective role against SCI via inhibiting oxidative stress, inflammation, lipid disorders, and ferroptosis, providing novel insights of the targeted therapy of SCI.
FIELD: medicine, surgery, traumatology. SUBSTANCE: invention relates to the prophylaxis and treatment of suppurative wound complications. Method involves the wound washing out with an antiseptic solution treated by ultrasonic oscillation. Silver-containing detergent poviargol at concentration 0.1-0.3% is used as an antiseptic. Method ensures to prevent the hospital infection. EFFECT: enhanced effectiveness of the method, decreased consumption of the preparation. 2 ex
The control group will benefit from the actual routine care for children with language delay before the age of 3 years. In order to provide them the best routine care, the psychologist will provide some advice to the parents to enhance their child's language (e.g.: using life situations to talk with the child and encourage him/her to talk ...).
The invention relates to a sterilizing tissue containing herbal ingredients. A non-woven fabric is taken as a base material. The sterilizing tissue is characterized by comprising chlorine dioxide, 1 to 1.5 percent of mint leaf extracts, 2 to 4 percent of propylene glycol, 0.5 percent of trichloro hydroxyl phenylate, 1 to 2 percent of borneol, 0.2 to 0.4 percent of Chinese mugwort leaf and 0.3 to 0.5 percent of Chinese gall. The sterilizing tissue also comprises a surfactant which is lauric acid fatty acid and/or glyceride. The PH value of the sterilizing tissue is 6. Active ingredients such as chlorine dioxide and trichloro hydroxyl phenylate are added into the sterilizing tissue containing herbal ingredients, and are spectral bactericides which are high in efficiency, low in toxicity and quick in sterilization, and the sterilizing tissue is strong in sterilizing ability and pollution-free; the ingredients such as mint leaf extracts, borneol, Chinese mugwort leaf and Chinese gall are added into the sterilizing tissue, so that an effect of protecting skin is achieved, and the sterilizing tissue has continuous efficacy and a pleasant fresh scent.
AHA reversibly inhibits the bacterial enzyme urease, thereby inhibiting the hydrolysis of urea and production of ammonia in urine infected with urea-splitting organisms. The reduced ammonia levels and decreased pH enhance the effectiveness of antimicrobial agents and allow an increased cure rate of these infections.

AHA is well absorbed from the gastrointestinal tract after oral administration; peak blood levels occur from 0.25 to 1 hour after dosing. The compound is distributed throughout body water, and there is no known binding to any tissue. AHA chelates with dietary iron within the gut. This reaction may interfere with absorption of AHA and with iron. Concomitant hypochromic anemia should be treated with intramuscular iron.

In rodents, the metabolic fate of AHA is well known; 55% is excreted unchanged in urine, 25% is excreted as acetamide or acetate and 7% is excreted by the lungs as carbon dioxide. Less than 1% is excreted in the feces. Approximately 5% of the administered dose is unaccounted for. In rodents, AHA shows a dose-related change in pharmacokinetics; with increasing dose, there is an increase in the half-life and an increase in the percent of the administered dose recovered in urine as unchanged AHA.

Pharmacokinetics in man are generally similar to rodents including the dose-related increase in half-life, but they are not as well characterized as in the rodent. Thirty-six to sixty-five percent (36-65%) of the oral dosage is excreted unchanged in the urine. It is unaltered AHA in the urine that provides the therapeutic effect, but the precise concentration of AHA in urine that is necessary to inhibit urease is incompletely delineated. Therapeutic benefit may be obtained from concentrations as low as 8 mcg/ml; higher concentrations (i.e., 30 mcg/ml) are expected to provide more complete inhibition of urease. The plasma half-life of AHA is approximately 5-10 hours in subjects with normal renal function and is prolonged in patients with reduced renal function.

Acetohydroxamic acid has been evaluated clinically in patients with urea-splitting urinary infections, often accompanied by struvite stone disease, that were recalcitrant to other forms of medical and surgical management. In these clinical trials, AHA reduced the pathologically elevated urinary ammonia and pH levels that result from the hydrolysis of urea by the enzyme, urease.

AHA does not acidify urine directly nor does it have a direct antibacterial effect. The usefulness of reducing ammonia levels and decreasing urinary pH is suggested by single (not yet replicated) clinical trials in which urease inhibition 1) allowed successful antibiotic treatment of urea-splitting Proteus infections after surgical removal of struvite stones in patients not cured by 3 months of antibacterial treatment alone, and 2) reduced the rate of stone growth in patients who were not candidates for surgical removal of stones.